Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock Has Average Target Price of $286.72

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been assigned a consensus rating of “Buy” from the nineteen brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $289.37.

A number of brokerages have recently weighed in on JAZZ. Canaccord Genuity Group set a $300.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 26th. Morgan Stanley raised their price objective on shares of Jazz Pharmaceuticals from $283.00 to $322.00 and gave the company an “overweight” rating in a research report on Wednesday, August 26th. Barclays boosted their target price on shares of Jazz Pharmaceuticals from $270.00 to $271.00 and gave the stock an “overweight” rating in a report on Thursday, September 10th. UBS Group increased their target price on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a “buy” rating in a research note on Friday, September 11th. Finally, The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a report on Thursday. They set a “buy” rating and a $337.00 target price for the company.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $236.28 on Friday. The company has a market cap of $15.34 billion, a PE ratio of 16.30, a P/E/G ratio of 0.22 and a beta of 0.36. Jazz Pharmaceuticals has a fifty-two week low of $125.79 and a fifty-two week high of $266.38. The firm has a 50-day simple moving average of $248.98 and a 200 day simple moving average of $227.51. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The business’s revenue was up 15.5% on a year-over-year basis. During the same period in the prior year, the business earned ($8.25) EPS. On average, sell-side analysts anticipate that Jazz Pharmaceuticals will post 21.5 EPS for the current year.

Insider Buying and Selling

In other news, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $240.94, for a total transaction of $289,128.00. Following the completion of the sale, the executive vice president directly owned 47,671 shares of the company’s stock, valued at $11,485,850.74. This represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the transaction, the executive vice president owned 65,686 shares of the company’s stock, valued at $16,401,794.20. This trade represents a 53.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 98,121 shares of company stock worth $24,443,842 over the last quarter. 4.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. USA Financial Formulas acquired a new stake in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $25,000. Ameritas Advisory Services LLC acquired a new position in Jazz Pharmaceuticals in the 2nd quarter worth approximately $47,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Jazz Pharmaceuticals during the 2nd quarter worth approximately $61,000. Westpac Banking Corp purchased a new position in Jazz Pharmaceuticals during the 1st quarter worth approximately $51,000. Finally, Leonteq Securities AG acquired a new stake in Jazz Pharmaceuticals during the 4th quarter valued at $50,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for disorders in neuroscience and oncology. The company concentrates on conditions with significant unmet medical needs, including sleep disorders, epilepsy, rare diseases and certain cancers.

Its neuroscience portfolio includes Xywav and Xyrem, oxybate-based treatments for narcolepsy, with Xywav also indicated for idiopathic hypersomnia in adults. Jazz also markets Epidiolex in the United States, known as Epidyolex in some international markets, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

In oncology, Jazz’s products include Rylaze, an asparaginase therapy used as part of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca, used for certain patients with metastatic small cell lung cancer; and Vyxeos, a chemotherapy formulation for certain cases of newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.